Day 1, Thursday, May 23rd
08:30-10:00 BCMA-targeted therapies in myeloma: the new treatment frontier
Pre-COMy CME Symposium
10:00-10:20 Coffee Break
10:20-10:30 COMy 2023 kick-off: Welcome by the Congress Co-Chairs
10:30-12:00 Session 1: Defining risk in myeloma
Moderators: Joan Bladé, Spain; TBA
10:30-10:45 MGUS risk stratification: Shaji Kumar, USA
10:45-11:00 Smoldering myeloma risk stratification: Irene Ghobrial, USA
11:00-11:15 Ultra high-risk disease in IMS consensus: Jill Corre, France
11:15-11:30 Genomic landscape of high-risk disease: Eileen Boyle, USA
11:30-11:45  Frailty as a risk stratifier: Ceri Bygrave, UK
11:45-12:00 Discussion: should we design risk-based protocols?
All session faculty and Hervé Avet-Loiseau, France & Vincent Rajkumar, USA
12:00-12:30 Lunch Break
12:30-14:00 Industry-supported Lunch Symposium
14:00-14:10 Technical Break
14:10-15:35 Session 2: Novel approaches for disease and response assessment
Moderators: Roberto Mina, Italy; Kwee Yong, UK
14:10-14:25 Optimizing MRD assessment: Bruno Paiva, Spain
14:25-14:40 Mass spectrometry: Noemi Puig, Spain
14:40-14:55 Immune monitoring in the context of immunotherapy: Niels van de Donk, Netherlands
14:55-15:10 Advances in imaging techniques: Elena Zamagni, Italy
15:10-15:25 The microbiota signature: Florent Malard, France
15:25-15:35 Discussion: should we design risk-based protocols?
All session faculty and Gordon Cook, UK & Jesús San Miguel, Spain
15:35-15:45 Technical Break
15:45-17:15 Industry-supported Symposium
17:15-17:30 Coffee Break
17:30-18:30 Session 3: Precursor conditions and other plasma cell disorders
Moderators: Michel Delforge, Belgium; Murielle Roussel, France
17:30-17:45 Screening for MGUS: hype or reality? Sigurdur Kristinsson, Iceland
17:45-18:00 Diagnosis and management of amyloidosis: Giampaolo Merlini, Italy
18:00-18:15 Diagnosis and management of Waldenström macroglobulinemia: Steven Treon, USA
18:15-18:30 Discussion: should we treat precursor conditions?
All session faculty and Bertrand Arnulf, France & Fredrik Schjesvold, Norway
18:30-19:15 Session 4: Plenary lectures
Moderators: Holger Auner, Switzerland; Charlotte Pawlyn, UK
18:30-18:50 Genomics of myeloma: the latest advances: Nikhil Munshi, USA
18:50-19:15 New mechanisms of disease resistance to T cell-based therapies: Paola Neri, Canada
Day 2, Friday, May 24th
07:00-07:30 Good Morning Breakfast
07:30-08:15 Breakfast Session
08:15-08:25 Technical Break
08:25-09:25 Session 5: IMS Session
Moderators: Philippe Moreau, France; Nikhil Munshi, USA
09:25-09:35 Technical Break
09:35-11:05 Industry-supported Morning Symposium
11:05-11:20 Coffee Break
11:20-12:30 Session 6: Frontline management of newly diagnosed myeloma
Moderators: Mario Boccadoro, Italy; TBA
11:20-11:35 The optimal induction prior to transplant: Francesca Gay, Italy
11:35-11:50 The role of double transplant: Hartmut Goldschmidt, Germany
11:50-12:05 The evolving landscape of maintenance therapy: Laura Rosiñol, Spain
12:05-12:20 The optimal approach in very old and frail patients: Thierry Facon, France
12:20-12:30 Discussion: should we continue to transplant myeloma?
All session faculty and Michele Cavo, Italy & Katja Weisel, Germany
12:30-13:00 Lunch Break
13:00-14:30 Industry-supported Lunch Symposium
14:30-14:45 Technical Break
14:45-15:45 Session 7: Practical management of specific situations
Moderators: Meral Beksac, Turkey; Lalit Kumar, India
14:45-15:00 Extra-medullary disease: Philippe Moreau, France
15:00-15:15 Therapy of patients under dialysis: Aurore Perrot, France
15:15-15:30 Bone disease: the latest guidelines: Evangelos Terpos, Greece
15:30-15:45 Vaccinations and infectious prophylaxis: Heinz Ludwig, Germany
15:45-16:00 Coffee Break
16:00-17:30 Industry-supported Symposium
17:30-17:45 Technical Break
17:45-18:45 Session 8: Plenary lectures
Moderators: Suzanne Lentzsch, USA; Saad Usmani, USA
17:45-18:00 CAR-T cells: present and future: Hermann Einsele, Germany
18:00-18:15 Bispecific antibodies: present and future: Nizar Bahlis, Canada
18:15-18:30 Minimizing toxicities after immunotherapy: Salomon Manier, France
18:30-18:45 Discussion: how to sequence immunotherapies?
All session faculty and Ajai Chari, USA & Thomas Martin, USA
18:45-19:45 Award Ceremony Session: Presented by the Congress Co-Chairs
Day 3, Saturday, May 25th
07:00-07:15 Good Morning Breakfast
07:15-08:00 Breakfast Session
08:00-08:10 Technical Break
08:10-09:10 Session 9: Novel agents under development
Moderators: Michael O’Dwyer, Ireland; Rakesh Popat, UK
08:10-08:25 CELMODs: Sagar Lonial, USA
08:25-08:40 Antibody-drug conjugates: Fredrik Schjesvold, Norway
08:40-08:55 Peptide conjugates: Enrique Ocio, Spain
08:55-09:10 How to bridge patients prior to CAR-T cells? Paul Richardson, USA
09:10-09:20 Technical Break
09:20-10:50 Is there a place for BCMA-based combinations in early RRMM?
Industry-supported Morning Symposium
10:50-11:10 Coffee Break
11:10-12:25 Session 10: How I treat a relapsed/refractory myeloma
Moderators: Bhagirathbhai Dholaria, USA;Joseph Mikhael, USA
11:10-11:25 Clinical case presentation + Treatment options (1st relapse after transplant):
Cyrille Touzeau, France
11:25-11:40 Clinical case presentation + Treatment options (1st relapse after anti-CD38+Rd):
Alessandra Larocca, Italy
11:40-11:55 Clinical case presentation + Treatment options (triple class refractory young patient):
Xavier Leleu, France
11:55-12:10 Clinical case presentation + Treatment options (triple class refractory elderly patient):
Hira Mian, Canada
12:10-12:30 Discussion
All session faculty and Claudio Cerchione, Italy & Joshua Richter, USA
12:30-13:00 Lunch Break
13:00-14:00 Industry-supported Lunch Symposium
14:00-14:10 Technical Break
14:10-14:55 Management of triple-class refractory patients in the absence of immunotherapies
Chairs: Mohamad Mohty, France; Lisa Leypoldt, Germany
14:10-14:25 Case study presentation: Bhagirathbhai Dholaria, USA
14:25-14:40 XPO-1 inhibition for refractory myeloma: Maximilian Merz, Germany
14:40-14:55 Discussion
All session faculty
14:55-16:10 Session 11: The road to cure: future protocols and directions
Moderators: Vincent Rajkumar, USA; TBA
14:55-15:10 Young and fit patients: Pieter Sonneveld, Netherlands
15:10-15:25 Elderly and/or frail patients: Sonja Zweegman, Netherlands
15:25-15:40 Protocols for low- and middle-income countries: Vania Hungria, Brazil
15:40-15:55 How to design the best protocol? Jean-Luc Harousseau, France
15:55-16:10 Patients’ perspective and advocacy: Brian Durie, USA
16:10-16:30 Coffee Break
16:30-17:30 CME Symposium
17:30-17:40 Technical Break
17:40-18:10 Session 12: Plenary lecture
Moderators: Congress Co-Chairs
17:40-18:10 Curing myeloma: from the bench to the bedside: Kenneth Anderson, USA
18:10-18:20 In-Person Conclusions: Summary by the Congress Co-Chairs
Day 4 (ONLINE ONLY), Sunday, May 26th
10:00-11:30 Multiple Myeloma communications I
11:30-12:30 CME Virtual Symposium
12:30-14:00 Multiple Myeloma communications II
14:00-14:30 Final Panel Discussion and Conclusion